2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Other Commercial Opportunities INJECTABLE ANTIBIOTICS In December 2012, Phosphagenics announced an agreement with Indian company Agila Specialities Private Limited to apply the TPM ® technology to a liquid injectable antibiotic. Agila will be meeting all the costs associated with the commercialisation of the product including all clinical trials required. 20 This represented a totally new area of application of the TPM ® technology and may open the door to a number of other opportunities. TPM ® improves the speed and solubility of the antibiotic powder being prepared prior to injecting into the patient. PHOSPHAGENICS ANNUAL REPORT 2012
Intellectual Property Title Countries Allowed Countries Pending Expiry A carrier comprising one Australia, Brazil, Japan, Canada, China, Europe, June 2026 or more di and/or mono- (electron transfer agent) phosphate derivatives Mexico, New Zealand, Russia, Singapore, South Africa Hong Kong, India, Israel, , South Korea, USA Alkaloid Formulations Australia, Canada, China, Brazil, Israel, USA March 2025 Europe, Hog Kong, India, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa Carrier Australia August 2023 Carrier Composition South Africa Australia, Brazil, Canada, China, Europe, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, USA Carrier Composition Australia, Brazil, Canada, China, Europe, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa, USA Carrier for Enteral Administration Complexes of Phosphate Derivatives December 2030 Feb 2031 Australia, China, Europe, Japan, Mexico, New Zealand, Russia, Singapore, South Africa Brazil, Canada, India, USA August 2025 Australia, Europe Brazil November 2021 Composition Australia, Europe, USA Feb 2031 Compounds Having Lipid Australia, Russia Canada, Europe, Japan, March 2026 Lowering Properties USA Dermal Therapy Australia, Canada, Japan, USA July 2022 Formulations containing Phosphate Derivatives of Electron Transfer Agents Improved Processes for Phosphorylation Australia, Canada, China, Europe, Japan, South Korea, Mexico, USA Australia, Brazil, Canada, Europe, Japan, Mexico, USA Brazil, Hong Kong November 2021 May 2020 New Composition PCT Stage March 2032 Transdermal Delivery Patch Australia, Brazil, Canada, March 2031 China, Europe, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa, Taiwan, USA Unpublished Applications Formulations Provisional Formulations Provisional 21 INTELLECTUAL PROPERTY
Page 1 and 2: 20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4: highlights March... April... May...
Page 5 and 6: 03 Jonathan Addison Chairman & Inde
Page 7 and 8: COLLABORATIONS Strategic Collaborat
Page 9 and 10: The Phosphagenics Evolution THE STO
Page 11 and 12: “ We also reached agreement with
Page 13 and 14: Overview of our opioid development
Page 15 and 16: 13 is branded as Butrans or Norspan
Page 17 and 18: Personal Care ASHLAND INC (FORMERLY
Page 19 and 20: BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21: cellulite contour crème BioElixia
Page 25 and 26: 2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28: DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30: Senior Management DR PAUL GAVIN Chi
Page 31 and 32: Phosphagenics Limited ABN 32 056 48
Page 33 and 34: Directors’ Report Your directors
Page 35 and 36: Directors’ Report continued Looki
Page 37 and 38: Directors’ Report continued Commi
Page 39 and 40: Directors’ Report continued REMUN
Page 43 and 44: Directors’ Report continued Share
Page 45 and 46: Directors’ Report continued Share
Page 47 and 48: Exercise Price Expiry Date Net othe
Page 49 and 50: Exercise Price Expiry Date Net othe
Page 51 and 52: Fair value per performance right at
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71 and 72: Notes to the consolidated fi nancia
Page 73 and 74:
Application date of standard Impact
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Notes to the consolidated fi nancia
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Independent Auditor’s Report 111
Page 115 and 116:
Additional Shareholder Information
Page 117 and 118:
Additional Shareholder Information
Page 119:
corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

Create successful ePaper yourself

Delete template?

Save as template?